Physician profile
Adebambo Ojuri
NPI 1679644983
$83,139.98
in general payments reported to CMS, 2019-2025
25 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $1,051 · 2021: $1,604 · 2022: $1,665 · 2023: $768 · 2024: $76K · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $75K · Food and Beverage: $2,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $74,784.17 |
| Food and Beverage | $2,982.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $74,784.17 | 2024 | Gastrointestinal Videoscope |
| Abbvie INC. | $2,581.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,873.92 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $861.60 | 2019-2024 | |
| Redhill Biopharma INC. | $551.27 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $405.18 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $398.18 | 2020-2024 | Dificid |
| Madrigal Pharmaceuticals | $361.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $324.26 | 2019-2025 | Entyvio |
| Pfizer INC. | $275.98 | 2019-2025 | |
| Allergan, INC. | $220.95 | 2019-2020 | |
| Janssen Biotech, INC. | $123.17 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Pentax of America, INC. | $61.64 | 2022 | |
| Celltrion USA INC. | $51.38 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $48.47 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $34.21 | 2020-2025 | |
| Ethicon US, LLC | $31.52 | 2019 | |
| Tersera Therapeutics LLC | $27.25 | 2022 | |
| Qol Medical, LLC | $27.16 | 2019 | |
| Celgene Corporation | $23.58 | 2022 | |
| Alcresta Therapeutics, INC. | $21.84 | 2024 | Relizorb |
| Medtronic, INC. | $19.81 | 2021 | |
| Vertiflex, INC. | $17.23 | 2019 | |
| Braintree Laboratories, INC. | $13.73 | 2024 | Suflave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adebambo Ojuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.